Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial
Kayo Horibe(Shiga University of Medical Science), Hiroshi Maegawa(Shiga University of Medical Science), Itsuko Miyazawa, Masahiro Yoshimura(Hyogo Prefectural Cancer Center), Keiko Kondo(Shiga University of Medical Science), Ryuta Itoh, Satoshi Ugi(Shiga University of Medical Science), Tsuyoshi Yanagimachi(Shiga University of Medical Science), Shogo Ida(Shiga University of Medical Science), Katsutaro Morino(Kagoshima University), Kiyoshi Murata(Surugadai University), Hisatomi Arima(University of Leicester), Daisuke Sato(Shiga University of Medical Science), Natsuko Ohashi(Shiga University of Medical Science), Yukihiro Fujita(Shiga University of Medical Science), Sachiko Tanaka‐Mizuno(Shiga University of Medical Science), Katsuyuki Miura(Shiga University of Medical Science)
Cited by 27
Related Papers
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
|JAMA|2014|982
Cardiovascular Disease and Risk Factors in Asia
|Circulation|2008|916
Molecular Mechanisms of Insulin Resistance in Humans and Their Potential Links With Mitochondrial Dysfunction
|Diabetes|2006|855
Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents
|Journal of Clinical Investigation|2005|805
A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen
|Journal of Human Hypertension|2002|722